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Abstract 
Objective: This study aimed to adapt the Addenbrooke’s Cognitive Examination-III (ACE-
III) and Mini-ACE (M-ACE) into Greek and then to examine the convergent validity against 
their predecessors Addenbrooke’s Cognitive Examination-Revised (ACE-R) and Mini-
Mental State Examination (MMSE) in a Greek population. Moreover, a primary aim was to 
appraise the utility of each screen by conducting a comparison of the psychometric properties 
of ACE-III, M-ACE, ACE-R, MMSE, and the Edinburgh Cognitive and Behavioural ALS 
Screen (ECAS) in detecting Alzheimer’s disease (AD). 
Methods: Forty patients with AD were recruited and matched with 38 controls. Bayesian 
Pearson’s correlation analysis was conducted to examine the convergent validity. Receiver 
operating characteristic curve analysis was implemented to appraise the sensitivity and 
specificity of the tests in detecting AD. 
Results: The ACE-III, M-ACE, and the ECAS scores robustly correlated with ACE-R and 
MMSE.  The ACE-III and the ECAS-ALS Non-Specific score were the most sensitive and 
specific tools in detecting AD, closely followed by ECAS Total score and M-ACE.  Only 
ECAS Total score correlated with the duration of disease. The ECAS scores were more 
resilient to ceiling effects than the other screens. M-ACE produced fewer ceiling effects than 
MMSE. 
Conclusion: The Greek ACE-III and M-ACE were successfully adapted and showed good 
convergent validity against their predecessors. They showed very good psychometric 
properties in detecting AD and may be considered in hectic clinical settings.  ECAS Total 
score and ECAS-ALS Non-Specific showed comparable psychometric properties in the 
detection of AD and may be considered in poly-pathological clinics where motor 
impairments are common. 
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Introduction 
Cognitive assessment is crucial for the detection of Alzheimer’s disease (AD) and for the 
differential diagnosis of other types of dementia, such as frontotemporal dementia (FTD) 
(Fields et al., 2011). Comprehensive assessment of cognition and behaviour has clinical 
implications for patient care, regarding the available treatment options, survival expectancy, 
competency to drive or provide informed consent, ability to live independently at home, the 
carer’s burden and quality of life (Hsieh et al., 2015). However, in hectic clinical settings, 
briefer cognitive screening methods are often the test of choice, with patients with more 
complex needs or diagnostic uncertainties being referred for full neuro-psychological 
assessment (Hsieh et al., 2015). 
Addenbrooke’s Cognitive Examination Revised (ACE-R) and the embedded Mini-Mental 
State Examination (MMSE) are the predominant brief screening tests for dementia in the 
Greek population, with administration times of approximately 15 and 5 min, respectively 
(Konstantinopoulou et al., 2011). Both of them were designed to briefly examine a wide 
range of cognitive domains: attention, memory, language, visuo-spatial components and 
verbal fluency (Mioshi et al., 2006). ACE-R aids in the detection, differentiation and 
monitoring of cognitive decline in dementia syndromes, such as FTD and AD (Hsieh et al., 
2012; Kipps et al., 2008; Mathew et al., 2011; Raimondi et al., 2012). 
However, ACE-R has several limitations (Hsieh et al., 2013); for example, healthy adults 
repeatedly fail on the verbal repetition item, which might be a result of hearing problems or 
distraction (Hsieh et al., 2013; Valcour et al., 2002), and ceiling effects have been observed 
in the measure of comprehension (Brugnolo et al., 2009). Acknowledging these weaknesses 
led to the development of Addenbrooke’s Cognitive Examination III (ACE-III). While the 
ACE-III does not incorporate MMSE, it continues to assess the same five cognitive domains, 
with new items in verbal repetition and language comprehension tasks, while backward 
spelling was replaced by serial 7s subtraction (Brugnolo et al., 2009; Ganguli et al., 1990; 
Hsieh et al., 2013; Valcour et al., 2002). 
ACE-III has been validated against extensive neuro-psychological tests (Hsieh et al., 
2015; Hsieh et al., 2013). However, even ACE-III, which demands 15–20 min to administer, 
has been suggested to be excessive for some busy clinical settings (Hsieh et al., 2015). Mini-
Addenbrooke’s Cognitive Examination (M-ACE) was subsequently developed, which 
appears to be more sensitive and specific than its widely used precursor, MMSE (Hsieh et al., 
2015; Folstein et al., 2001). 
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) was recently developed 
(Abrahams et al., 2014) and adapted for the Greek (Kourtesis et al., 2019), Italian (Poletti et 
al., 2016), German (Lule et al., 2015), Chinese (Ye et al., 2016) and Spanish (Mora et al., 
2018) populations. ECAS is also a brief assessment similar to ACE-III, but it was designed 
for patients with various motor impairments and was found to be sensitive in amyotrophic 
lateral sclerosis (ALS), Parkinson’s disease and progressive supranuclear palsy (Foley et al., 
2018; Niven et al., 2015; Strong et al., 2017). ECAS has been specifically designed to detect 
the type of cognitive and behavioural impairment in ALS of an executive nature similar to 
that found in FTD. ECAS comprises an ALS-specific component (executive function and 
social cognition, verbal fluency and language) and a carer’s interview to detect the 
behavioural and psychotic changes typical in FTD. This focus on executive functions 
distinguishes ECAS from ACE-III. However, the ECAS was also designed to assess the 
functions typically affected in other diseases common in older adults, such as AD, and 
therefore it includes an ALS Non-Specific segment (memory and visuo-spatial function) 
(Foley et al., 2018; Niven et al., 2015; Strong et al., 2017). We have previously demonstrated 
that the ALS Non-Specific score is highly sensitive and specific in identifying the cognitive 
changes typical of AD and helps differentiate AD from ALS (Kourtesis et al., 2019). 
In this study, aimed to adapt the ACE-III and M-ACE and to examine their convergent 
validity against their predecessors, ACE-R and MMSE, in a Greek population. Moreover, our 
primary aim was to compare these screening tools (ACE-III, M-ACE, ACE-R, MMSE and 
ECAS) in detecting AD in a Greek population.  
Methods 
Participants  
All the participants and their carers signed an informed consent form in compliance with the 
revised Declaration of Helsinki (1987). This study was approved by the Psychology Research 
Ethics Committee of the University of Edinburgh, as well as the Aeginition Hospital Ethics 
Committee. All the participants were native Greek speakers and free from the following: (1) 
psychiatric disorders; (2) psychoactive drugs, antidepressants and anticonvulsants, (3) other 
neurological conditions affecting cognition; (4) learning disabilities; (5) alcoholism and drug 
abuse and (6) uncontrolled systemic diseases. 
Patients with AD  
The attendants of the Maroussi Alzheimer Clinic of the Athens Association of Alzheimer 
Disease and Related Disorders, Athens, Greece, were employed for this study. A total of 40 
patients with AD participated; a sub-sample has previously been described by Kourtesis et al. 
(2019). Recruitment was conducted in accordance with the general inclusion criteria and the 
following criteria specific to AD: (1) a diagnosis of AD according to the National Institute of 
Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related 
Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984) and (2) the absence of 
mixed concomitant dementia processes (e.g. AD and vascular dementia). In addition, a 
neuropsychologist or psychiatrist interviewed the patients and administered the Hospital 
Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) (cut-off ≥ 8) to exclude 
patients with major depression or anxiety symptoms that may compromise their performance. 
The duration of the disease was calculated in years, from the onset of the first symptoms to 
the testing date. 
Healthy Subjects 
In this study, 38 controls were recruited and matched in age, sex and education to the patient 
group. They belonged to one of the following categories: (1) members of Athens Association 
of Alzheimer Disease and Related Disorders, Athens, Greece; (2) relatives of patients with 
AD or (3) volunteers who responded to the calls of the above association. For recruitment, we 
implemented the aforementioned general inclusion criteria.  
Procedures  
Translation-Adaptation 
Adaptation of ACE-III and embedded M-ACE required minor adjustments as the 
administration (e.g. instructions) of the majority of the tasks was similar to that of ACE-R. 
The most significant adjustment, in terms of translation, was in the section of language in the 
task of proverb repetition, in which the pronunciation of proverbs is required. In terms of 
pronunciation, the first item should be a low-difficulty proverb (i.e. ‘All that glitters is not 
gold’), and the second item should be a medium-to-hard-difficulty proverb (i.e. ‘A stitch in 
time saves nine’). The proverbs of the Greek version were culturally adjusted, and the 
counterparts of this difficulty measure were ‘All that glitters is not gold’ and ‘Better donkey-
tying than donkey-seeking’. The original version of ACE-III (in which the M-ACE is 
embedded) was adapted to the Greek language using the back-translation method. The 
original English version was translated into Greek by a native Greek speaker fluent in 
English, and then it was translated back into English by a native speaker of both Greek and 
English who was also blind to the original version of ACE-III. The procedure of 
translation/back translation was successful in only two iterations as there were mainly minor 
amendments compared to ACE-R. Finally, the adaptation of ECAS in Greek was described 
by Kourtesis et al. (2019).  
Administration of the Tests and Inter-Rater Reliability 
Administration of the tests was randomised to control for a possible practice effect (Benedict 
& Zgaljardic, 1998). Inter-rater reliability was calculated between the scores for ACE-III and 
M-ACE provided by the assessors and the independent reviewer. The four assessors and the 
independent reviewer were trained equally in the administration and scoring of ACE-III and 
M-ACE based on relevant guidelines. The independent reviewer was blinded to the identity 
of the examiner as well as the examinee. 
Statistical Analyses 
Bayesian statistics were preferred over null hypothesis significance testing (NHST). The 
Bayesian factor (BF10) has been found to be more parsimonious than the p-value in 
evaluating evidence against H0 (Cox & Donnelly, 2011; Held & Ott, 2018; Wagenmakers et 
al., 2018a; Wagenmakers et al., 2018b). Importantly, the difference between BF10 and p-
values is even greater (in favour of BF10) in small sample sizes, which is pertinent to the 
present study (Held & Ott, 2018; Wagenmakers et al., 2018a; Wagenmakers et al., 2018b). A 
larger BF10 postulates more evidence in support of H1 (Cox & Donnelly, 2011; Held & Ott, 
2018; Marsman & Wagenmakers, 2017; Wagenmakers et al., 2018a; Wagenmakers et al., 
2018b). In this study, a threshold of BF10 ≥ 10 was set for statistical inference, which 
postulates strong evidence in favour of H1 (Marsman & Wagenmakers, 2017; Wagenmakers 
et al., 2018a; Wagenmakers et al., 2018b), and corresponds to a p-value of < 0.01 (e.g. BF10 = 
10) or to a p-value of <0.001 (e.g. BF10 > 11) (Cox & Donnelly, 2011; Held & Ott, 2018). 
However, we report both BF10 and p-values in this study. Finally, BF10 allows evidence in 
either direction (i.e. towards H1 and H0), and its measurement of evidence is insensitive to 
the stopping rule, which substantially mitigates the multiple comparisons problem and 
generates reliable and more generalisable results (Dienes, 2016; Marsman & Wagenmakers, 
2017; Wagenmakers et al., 2018b). 
The inter-rater reliability between the assessors who administered the screening 
procedures and the independent interviewer was appraised using the Intra-Class Correlation 
Coefficient (ICC), which displays outcomes from ‘no match’ = 0 to ‘seamless match’ = 1 
(Weir, 2005). The internal consistency of the Greek ACE-III and M-ACE was determined by 
calculating Cronbach’s alpha coefficient. A Cronbach’s alpha coefficient of 0.70 or greater is 
considered substantial (Nunnaly, 1994). Demographic and cognitive data were analysed and 
compared. Shapiro–Wilk’s test revealed non-significant results (i.e. normal distribution) for 
every variable. Between-group comparisons were made using Bayesian independent samples 
t-tests. The convergent validity of the screening tools was examined in the whole sample 
(𝑁 = 78, i.e. HC = 38 + AD = 40). The convergent validity and associations between the 
screening tools were probed and quantified using Bayesian Pearson’s correlation analysis to 
ensure that our results are more reliable and generalisable. Receiver operating characteristic 
(ROC) curve analyses and area under the curve (AUC) were implemented to appraise the 
psychometric properties of the screening methods. All statistical analyses were performed 
using SPSS Statistics v.24.0 (scale, ROC and AUC analyses) (Release 2016; IBM Corp., 
Armonk, NY, USA) and JASP v.0.8.1.2 (Bayesian Pearson’s correlation analyses, Bayesian 
independent samples t-tests) (JASP Team, 2017). Finally, a post hoc analysis (i.e. the 
achieved statistical power) of the Bayesian Pearson’s correlations (i.e. the convergent validity 
of the screening methods) was performed using G*Power (Faul et al., 2007; Faul et al., 
2009).  
Results  
Inter-Rater Reliability & Internal Consistency 
The inter-rater reliability demonstrated an almost seamless agreement between the assessors, 
indicating substantial suitability for clinical measures (Weir, 2005). An ICC value of 0.92 
was found for ACE-III and M-ACE (Weir, 2005). The scale analyses demonstrated excellent 
internal consistency of ACE-III and M-ACE with Cronbach’s alpha = 0.79 (Nunnaly, 1994). 
We also inspected the internal consistency of ACE-III by replacing the repetition task of the 
culturally adjusted proverbs with the repetition task of phrases in ACE-R. The internal 
consistency of ACE-III with the repetition task of phrases (ACE-R) dropped to 0.77, 
indicating that the new repetition task of culturally adjusted proverbs contributed to the 
improvement of the internal consistency of ACE-III. 
 
Convergent Validity 
The Bayesian Pearson’s correlation analyses robustly supported the convergent validity of 
ACE-III and M-ACE, as well as ECAS and its sub-scores, by indicating a large effect size 
(i.e. Pearson’s 𝑟 varied from 0.845 to 0.976), highly significant 𝑝-values (i.e. 𝑝 < 0.001), 
highly extreme evidence of the Bayesian factor analysis (e.g. BF10 = 1.299e+33) and an 
almost perfect statistical power (i.e. ≈100%). The statistics for the Bayesian Pearson’s 
correlations are displayed in Table 1. ACE-III displayed a robust correlation with ACE-R. 
Equally, M-ACE substantially correlated with MMSE. Moreover, ECAS and its sub-scores 
significantly correlated with ACE-R.  
Table 1 – Convergent validity: Bayesian Pearson’s correlations 
BF= Bayes Factor; * BF₁₀ > 10 ** BF₁₀ > 30, *** BF₁₀ > 100; For post hoc statistical power α < .001   
 
Sensitivity and Specificity in the Detection of AD 
ROC and AUC analyses were executed to explore the psychometric properties of the screens 
in detecting AD. Figure 1 presents the ROC curves of each screen and sub-score. All the tests 
confirmed an adequately high level of sensitivity and specificity. Additionally, the analysis 
computed the sensitivity and specificity respective to different cut-offs, and the optimum cut-
off to determine abnormality is shown (see Table 2). The ACE-III, ECAS, ACE-R, M-ACE, 
and ECAS-ALS Non-Specific covered the greatest AUC. 
 
 
 
 
Correlational Pairs Pearson’s r p-value Statistical Power BF₁₀ 
ACE-R & ACE-III 0.976 *** p< .001 ≈100% 6.009e+253 
MMSE & M-ACE 0.863 *** p< .001 ≈100% 1.299e+33 
ACE-R & ECAS Total Score 0.924 *** p< .001 ≈100% 2.172e+69 
ACE-R & ECAS ALS-Specific 0.911 *** p< .001 ≈100% 2.589e+57 
ACE-R & ECAS ALS Non-Specific 0.845 *** p< .001 ≈100% 1.286e+28 
Figure 1- ROC curves: differentiation between patients with AD and controls   
 
 
 
 
 
 
 
 
 
 
Table 2– Sensitivity and specificity in the detection of AD 
Screen AUC PPV NPV PLR NLR Cut-off Sensitivity Specificity 
ACE-III 99.7% 97.4% 97.4% 37.5 37.5 83.00 94.7% 100% 
 84.00 97.4% 97.4% 
         
M-ACE 99.1% 94.9% 97.3% 18.4 36.4 23.00 97.4% 94.7% 
         
ACE-R 99.0% 100% 92.7% 92.1 12.5 82.00 89.5% 100% 
 84.00 92.1% 100% 
         
MMSE 94.5% 91.7% 87.5% 11.0 7.0 22.00 76.3% 97.4% 
 24.00 86.8% 92.1% 
         
ECAS 99.8% 97.3% 94.9% 36.4 18.4 93.00 92.1% 100% 
 94.00 94.7% 97.4% 
         
ECAS ALS 
Specific 
98.4% 89.7% 91.9% 08.8 11.3 68.00 84.2% 94.7% 
 71.00 92.1% 89.5% 
         
ECAS ALS 
Non-Specific 
99.7% 97.4% 97.4% 37.5 37.5 23.00 86.8% 100% 
 24.00 97.4% 97.4% 
The current cut-offs (2 SDs from the mean) are displayed first; The cut-ffs with highest sensitivity or specificity 
are presented. The proposed cut-offs (based on optimal sensitivity and specificity values) are showed in bold. 
Where the current and proposed cut-offs are the same only one value is given;  
AUC = Area Under Curve; PPV = Positive Predictive Value; NPV = Negative Predictive Value;  
PLR = Positive Likelihood Ratio; NLR = Negative Likelihood Ratio 
 
Cognitive Performance and Behavioural Changes in AD   
In the whole sample, there were no associations between cognitive performance and 
age/education. In group comparisons, patients with AD performed significantly worse than 
healthy controls in every test (see Table 3). In the AD sample, the HADS scores (i.e. 
depression and anxiety) did not correlate with cognitive performance. In addition, we 
examined the correlation between the screening methods and the duration of disease in the 
sample of patients with AD. Robust correlations with the duration of disease were detected 
solely with the total score of ECAS (BF10 = 14.22), whereas with the rest of the screening 
methods and sub-scores the correlations were non-significant (see Table 4). 14 patients (35%) 
had a disease duration of less than three years and 26 patients (65%) had a disease duration of 
three to six years, indicating that the sample of patients were in the early and early-middle 
stages of AD. Furthermore, the carers of 16 out of 40 patients with AD (40%) reported 
behavioural changes in the ECAS Behavioural Interview. The most prominent behavioural 
changes were apathy and loss of sympathy with some describing disinhibition (see Figure 2), 
whereas none of the carers reported a behavioural change pertaining to the rest of the ECAS 
behavioural items (i.e. compulsion, hyperorality and psychosis).  
Table 3 – Comparison between controls and patients with AD 
 Controls – Mean (SD) AD – Mean (SD) p-value BF₁₀ 
N = 78 38 40   
Sex 20M / 18F 19M / 21F p = .646 (Chi2 test) 
Age 72.55 (6.32) 74.74 (6.05) p = .128 0.103 
Education 12.26 (3.20) 11.61 (3.25) p = .377 0.531 
ACE-III 
(Max Score = 100) 
92.16 (4.08) 61.18 (16.86) p < .001 ***2.447e +14 
M-ACE 
(Max Score = 30) 
27.05 (2.16) 15.16 (6.06) p < .001 ***1.178e +15 
ACE-R 
(Max Score = 100) 
92.03 (3.82) 62.29 (17.03) p < .001 ***3.067e +13 
 
MMSE 
(Max Score = 30) 
27.53 (2.05) 19.37 (5.35) p < .001 ***2.475e +10 
ECAS Total Score 
(Max Score = 100) 
109.61 (8.30) 68.82 (18.08) p < .001 ***1.615e +17 
 
ECAS-ALS Specific 
(Max Score = 100) 
80.37 (6.26) 53.45 (14.03) p < .001 ***1.051e +14 
 
ECAS-ALS Non-Specific 
(Max Score = 36) 
29.24 (2.74) 15.37 (6.16) p < .001 ***1.953e +17 
 
SD = Standard Deviation; BF= Bayes Factor; * BF₁₀ > 10, ** BF₁₀ > 30, *** BF₁₀ > 100 
 
 
 
 
Table 4 – Bayesian Pearson’s correlations with the duration of disease 
BF= Bayes Factor; * BF₁₀ > 10, ** BF₁₀ > 30, *** BF₁₀ > 100 
 
Figure 2- ECAS Behavioural Interview: behavioural changes in AD
 
Ceiling Effects in the Screens 
The ECAS scores appear to be substantially more resilient to ceiling effects compared to 
ACE-III, ACE-R (Figure 3) and, M-ACE and MMSE (Figure 4). Ceiling effects in the last 
two short screens were pronounced (see Figures 3 and 4). Lastly, only four patients with AD 
(out of 40, i.e. 10%) failed to collect two points (i.e. maximum points) in the phrase repetition 
task of ACE-R, whereas 10 patients with AD (i.e. 25%) failed to collect the maximum points 
in the proverb repetition task of ACE-III. 
Correlational Pairs Pearson’s r p-value BF₁₀ 
Disease Duration & ACE-III -0.307 p>.05 2.306 
Disease Duration & M-ACE -0.215 p = 0.91 0.839 
Disease Duration & ACE-R -0.338 p< .05 3.464 
Disease Duration & MMSE -0.108 p = 0.25 0.360 
Disease Duration & ECAS Total Score -0.424 * p< .01 14.222 
Disease Duration & ECAS ALS-Specific -0.392 p< .01 7.995 
Disease Duration & ECAS ALS Non-Specific -0.348 p< .05 4.010 
Figure 3- Distribution of healthy controls’ performance in the fourth quartile of the possible scores  
 
 
 
 
 
 
 
 
 
 
 
 
         ECAS Total Score - Maximum Score = 136                      ACE-R - Maximum Score = 100 
  
                     
        ECAS  ALS Specific - Maximum Score = 100                                       ACE-III - Maximum Score = 100 
 
Figure 4- Distribution of healthy controls’ performance in the third tier of the possible scores 
 
 
Discussion 
The present study successfully produced the Greek versions of ACE-III and M-ACE. The 
tests showed robust convergent validity against the already adapted and validated Greek 
versions of ACE-R and MMSE as evidenced by the large effect size, the high significance of 
the correlations, the strong evidence of the Bayesian factor analysis, and the almost perfect 
statistical power. Furthermore, the screening methods exhibited substantial internal 
consistency, which allows for implementation in clinical and research settings (Nunnaly, 
1994). The tests also showed almost excellent inter-rater reliability, permitting extensive 
utilisation by various clinical practitioners (Weir, 2005). Therefore, the Greek ACE-III and 
M-ACE can be considered as suitable tools for clinical and research purposes. 
 
      ECAS ALS Non-Specific - Maximum Score = 36                      M-ACE - Maximum Score = 30 
  
 
                           MMSE - Maximum Score = 30 
 
Detection of Alzheimer’s Disease in a Greek Population 
ACE-III elicited 94.7% sensitivity and 100% specificity at a cut-off of 83 (2 SDs), as well as 
97.4% sensitivity and 97.4% specificity at a cut-off of 84, in the detection of dementia within 
a sample pool of patients with AD who were predominantly in their first to fourth years after 
diagnosis. The sensitivity of ACE-III (94.7% and 97.4%) was superior to that of ACE-R 
(89.5% and 92.1%), demonstrating that ACE-III should be the tool of choice against ACE-R.  
A comparison of M-ACE to MMSE revealed superior psychometrics in the former with 
97.4% sensitivity and 94.7% specificity at a cut-off of 23 (MMSE, 86.8% sensitivity and 
92.1% specificity at a cut-off of 24). The higher sensitivity and comparable specificity to 
MMSE are aligned with the validation study of M-ACE (Hsieh et al., 2015). Accordingly, M-
ACE surfaces as the most appropriate brief screening tool for detecting AD. M-ACE may be 
considered in hectic clinical environments, in which brief screening procedures are preferred. 
Furthermore, the ECAS-ALS Non-Specific score was equally able to detect AD 
compared to the ACE-III with 97.4% sensitivity and specificity at a cut-off of 24. In addition, 
the ECAS-ALS Non-Specific score was substantially more specific than M-ACE but was 
equally sensitive. However, the sensitivity of the total score of ECAS was slightly below that 
of ACE-III and M-ACE although specificity was comparable. Of note the ECAS Total score 
was the only score that correlated with the disease duration, indicating that it may be more 
sensitive to cognitive decline than the rest of the screens, although this has yet to be 
demonstrated. Lastly, the ECAS-ALS Specific score appears to be less sensitive and specific 
compared to the above screening methods, although it displayed good psychometric 
properties in the identification of AD. 
 Utility of the Screens 
The Greek version of ACE-III contains a repetition task of culturally adjusted proverbs, 
which replaced the repetition task of phrases in ACE-R. These items appeared to contribute 
to the internal consistency of ACE-III, and were less prone to ceiling effects in the AD group 
compared to the equivalent task of ACE-R. However, both tests suffered from ceiling effects 
in contrast to the ECAS. These were most pronounced in the shorter screening tools (M-ACE 
and MMSE, although, the former was marginally less prone than the latter, which is in line 
with the findings of Hsieh et al. (2015). However, the ECAS-ALS Non-Specific score and in 
particular the ECAS Total score and ECAS-ALS Specific did not suffer from ceiling effects. 
These findings are in line with the findings of a previous study in which ECAS was found to 
be substantially less dependent on IQ and produced significantly fewer ceiling effects 
compared to ACE-III, which may be an advantage for use with clinical groups (De Icaza 
Valenzuela et al., 2018). 
Furthermore, ACE-III does not include a behavioural assessment, which is a shortcoming 
(Hsieh et al., 2013). In contrast, the ECAS has a Behavioural Interview, which may add to the 
cognitive profile of the patient and predict caregiver’s burden. In the current study, 40% of 
the carers of patients with AD reported behavioural changes. The most prominent were 
apathy and loss of sympathy. However, the ECAS Behavioural does not assess 
comprehensively apathy. Apathy is considered a multi-dimensional construct incorporating 
emotional, executive and initiation dimensions (Caga et al., 2018; Marin, 1991; Radakovic & 
Abrahams, 2018). Recently, the Dimensional Apathy Scale (DAS) was developed to assess 
these constructs (Radakovic & Abrahams, 2014). Notably, the DAS was implemented in AD, 
where a heterogenous profile emerged, enabling classification into three distinct groups 
(Radakovic et al., 2017). Hence, the DAS may be used in conjunction with ACE-III or ECAS 
in order to further identify and differentiate the types of apathy, which may be of clinical 
relevance. 
Moreover, ACE-III and M-ACE are not adjusted to motor impairments, whereas ECAS is 
adjusted to upper motor and speech impairments. In a previous study, the ECAS-ALS Non-
Specific score displayed very good psychometric properties in differentiating patients with 
AD from non-demented patients with ALS, whereas ACE-III and M-ACE were not 
successful (Kourtesis et al., 2019). Therefore, the ECAS might be considered as an 
appropriate tool in patients with motor dysfunction, which are common in many neuro-
degenerative diseases, and could be ideally included in future clinical trials.  
Limitations & Future Studies   
This study contains certain caveats that should be noted. One of the limitations of this study 
is the small sample size albeit the facilitation of robust statistical analyses with high statistical 
power. A larger and more diverse sample would allow more solid and conclusive 
observations. In future studies, the acquisition of normative data should be of a size that 
permits the computation of distinct cut-off scores that are analogous to the educational level. 
Only patients with AD were recruited in this study. It would be of relevance to investigate 
the capacity of the tests to differentiate between patients with FTD and AD and probe FTD 
phenotypes. In addition, future studies should consider adapting a scale such as the DAS in 
Greek, which may assist with research and/or clinical endeavours. The extensive and 
profound study of cognitive and behavioural changes in patients with dementia can help 
ameliorate and adjust patient care and alleviate the caregivers’ burden. 
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